Danaher Corp. (DHR)

102.05
1.60 1.60
NYSE : Health Technology
Prev Close 100.49
Open 100.72
Day Low/High 100.49 / 101.92
52 Wk Low/High 78.97 / 104.82
Volume 891.60K
Avg Volume 2.44M
Exchange NYSE
Shares Outstanding 698.57M
Market Cap 69.93B
EPS 3.60
P/E Ratio 27.73
Div & Yield 0.64 (0.57%)

Latest News

Market Weakness Shows Need For Discipline

Sales into strength leave us with money to put to work during earnings season.

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Stocks on Wall Street declined Thursday amid a host of earnings reports.

Adding to Nordstrom

Today's weakness is the opportunity we have been patiently waiting for.

Jim's Daily Rundown

Jim discusses earnings from Nucor and Danaher, recent headlines about Apple, Amazon, Allergan, and more!

Danaher Reports 1Q Result

Overall, it was another great quarter for Danaher.

Starbucks Leaves a Bitter Taste and Doesn't Suit My Investment Palate Either

Starbucks Leaves a Bitter Taste and Doesn't Suit My Investment Palate Either

For my portfolio, you can't beat this SBUX competitor -- and for a cup of coffee.

Amazon, Procter & Gamble, Southwest and Netflix - 5 Things You Must Know

Amazon, Procter & Gamble, Southwest and Netflix - 5 Things You Must Know

U.S. stock futures point lower; surging oil prices boost equities in Europe and Asia; Amazon says its Prime subscription program has more than 100 million members; P&G to buy German Merck's consumer healthcare unit for $4.2 billion.

Dropbox, Qualcomm, Skechers: 'Mad Money' Lightning Round

Dropbox, Qualcomm, Skechers: 'Mad Money' Lightning Round

Jim Cramer focuses on Dropbox, Qualcomm, Skechers USA, Spotify, Nucor, Kratos Defense & Security, American Water Works.

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

How do you get a stock moving? Jim Cramer says the answer is to invest in technology.

Revance Therapeutics: Cramer's Top Takeaways

Revance Therapeutics: Cramer's Top Takeaways

Dan Browne, co-founder, president and CEO of Revance Therapeutics, tells Jim Cramer his company is developing an alternative to Botox.

CyrusOne: Cramer's Top Takeaways

CyrusOne: Cramer's Top Takeaways

Gary Wojtaszek, president and CEO of CyrusOne, tells Jim Cramer about the $442 million acquisition of Zenium.

Trimming Illinois Tool Works and Danaher

We continue to look for opportunities to lock in strong profits and build up our cash position

Seven Portfolio Companies Report This Week

Latest results due from UnitedHealth, Goldman Sachs, Abbott and more.

Weekly Roundup

The markets bounced back on easing trade tensions and the banks kicked off first-quarter earnings season.

Keeping Cash Ready For the Right Moment

Increased volatility makes it more important than ever to maintain discipline and keep cash ready.

Weekly Roundup

Fears of a trade war and a Fed rate hike marked a volatile week.

Weekly Roundup

White House gets new economic adviser.

Weekly Roundup

Trump signs tariffs...markets recover

Danaher's Positive Preannouncement; More Thoughts on Today's Selling

If the market comes in further, we are ready to take advantage of opportunities in select names.

Jim's Daily Rundown

Jim discusses Gary Cohn's resignation, Friday's job report, and Danaher's preannounced Q1 earnings.

Weekly Roundup

Volatility picked up this week due to news from Washington.

General Electric Announces Board Slate, Introduces Three Director Candidates

General Electric Announces Board Slate, Introduces Three Director Candidates

The Boston-based company nominated Lawrence Culp Jr., Thomas Horton and Leslie Seidman.

Weekly Roundup

We added one FANG name and trimmed others as markets remained volatility.

Danaher Announces Quarterly Dividend

Danaher Announces Quarterly Dividend

Weekly Roundup

Markets rebound this week.

TheStreet Quant Rating: A- (Buy)